Total Funding
31
10
Total FundingSeries C raised
Growth Score
-3 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
314028
Wellesley Pharmaceuticals ensures that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated.
- David Dill: CEO and President
About the Company
Wellesley Pharmaceuticals ensures that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated. Wellesley Pharmaceuticals is in the development of an innovative, patented drug for treating Nocturia (frequent urination at night). Currently, there are no drugs on the market focused on nocturia and Wellesley
plans to be first to market in the space. They believe that their proprietary drug, Paxerol, positions them to be the industry leader, addressing a massive unmet clinical need.
Paxerol offers a significant advancement in terms of mechanism of action relative to existing indirect treatments of nocturia and should allow them to provide relief to hundreds of millions of people.
